About: Incidence, risk factors, and prognosis of abnormal liver biochemical tests in COVID-19 patients: a systematic review and meta-analysis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Incidence, risk factors, and prognosis of abnormal liver biochemical tests in COVID-19 patients: a systematic review and meta-analysis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Incidence, risk factors, and prognosis of abnormal liver biochemical tests in COVID-19 patients: a systematic review and meta-analysis
Creator	Li, Hongyu Guo, · Fernando, · Battista, Giovanni Mendez-Sanchez, Nahum Qi, · Romeiro, Gomes Sandri, Levi Shukla, Akash Teschke, Rolf Wu, Yanyan Yoshida, Eric
Source	Medline; PMC
abstract	BACKGROUND AND AIMS: Coronavirus disease 2019 (COVID-19) pandemic is ongoing. Except for lung injury, it is possible that COVID-19 patients develop liver injury. Thus, we conducted a systematic review and meta-analysis to explore the incidence, risk factors, and prognosis of abnormal liver biochemical tests in COVID-19 patients. METHODS: PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), VIP, and Wanfang databases were searched. The incidence of abnormal liver biochemical tests, including aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), gamma-glutamyl transpeptidase (GGT), total bilirubin (TBIL), and albumin (ALB), was pooled. Risk ratio (RR) was calculated to explore the association of abnormal liver biochemical tests with severity and prognosis of COVID-19 patients. RESULTS: Forty-five studies were included. The pooled incidence of any abnormal liver biochemical indicator at admission and during hospitalization was 27.2% and 36%, respectively. Among the abnormal liver biochemical indicators observed at admission, abnormal ALB was the most common, followed by GGT, AST, ALT, TBIL, and ALP (39.8%, 35.8%, 21.8%, 20.4%, 8.8%, and 4.7%). Among the abnormal liver biochemical indicators observed during hospitalization, abnormal ALT was more common than AST and TBIL (38.4%, 28.1%, and 23.2%). Severe and/or critical patients had a significantly higher pooled incidence of abnormal liver biochemical indicators at admission than mild and/or moderate patients. Non-survivors had a significantly higher incidence of abnormal liver biochemical indicators than survivors (RR = 1.34, p = 0.04). CONCLUSIONS: Abnormal liver biochemical tests are common in COVID-19 patients. Liver biochemical indicators are closely related to the severity and prognosis of COVID-19 patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s12072-020-10074-6) contains supplementary material, which is available to authorized users.
has issue date	2020-07-24(xsd:dateTime)
bibo:doi	10.1007/s12072-020-10074-6
bibo:pmid	32710250
has license	no-cc
sha1sum (hex)	64f3a0f5d40d59d9a543041ff2baab8cba76aaf3
schema:url	https://doi.org/10.1007/s12072-020-10074-6
resource representing a document's title	Incidence, risk factors, and prognosis of abnormal liver biochemical tests in COVID-19 patients: a systematic review and meta-analysis
has PubMed Central identifier	PMC7380163
has PubMed identifier	32710250
schema:publication	Hepatol Int
resource representing a document's body	covid:64f3a0f5d40d59d9a543041ff2baab8cba76aaf3#body_text
is schema:about of	named entity 'liver' named entity 'abnormal' named entity 'Wanfang' named entity 'biochemical' named entity 'AST' named entity 'liver' named entity 'meta-analysis' named entity 'COVID-19' named entity 'BIOCHEMICAL TESTS' named entity 'RISK RATIO' named entity 'NON-' named entity 'FOLLOWED BY' named entity 'LIBRARY' covid:arg/64f3a0f5d40d59d9a543041ff2baab8cba76aaf3 named entity 'higher' named entity 'admission' named entity 'PubMed' named entity 'liver' named entity 'Risk ratio' named entity 'abnormal' named entity 'AST' named entity 'alkaline phosphatase' named entity 'aspartate aminotransferase' named entity 'prognosis' named entity 'COVID-19' named entity 'Embase' named entity 'Wanfang' named entity 'GGT' named entity 'gamma-glutamyl transpeptidase' named entity 'COVID-19' named entity 'risk factors' named entity 'PubMed' named entity 'biochemical' named entity 'liver' named entity 'prognosis' named entity 'systematic review' named entity 'biochemical tests' named entity 'biochemical' named entity 'statistically significant' named entity 'liver' named entity 'liver injury' named entity 'COVID' named entity 'Meta-analyses' named entity 'liver' named entity 'COVID' named entity 'liver' named entity 'placenta' named entity 'Meta-analyses' named entity 'COVID' named entity 'pneumonia' named entity 'vasopressor' named entity 'biochemical tests' named entity 'biochemical' named entity 'Epidemiology' named entity 'biochemical tests' named entity 'GGT' named entity 'COVID-19' named entity 'subgroup analysis' named entity 'infection' named entity 'liver injury' named entity 'liver injury' named entity 'reperfusion' named entity 'liver' named entity 'SARS-CoV-2' named entity 'bile duct' named entity 'TBIL' named entity 'GGT' named entity 'animal studies' named entity 'subgroup analyses' named entity 'regression analyses'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software